Tandem Diabetes Care, Inc.’s TNDM impressive international expansion is expected to bolster growth in the upcoming quarters. The company’s impressive strategic initiatives provide a favorable ...

The FDA cleared an updated algorithm for a hybrid closed-loop insulin delivery system that permits users to set a lower ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Inhaled Technosphere insulin (TI) failed to meet noninferiority for HbA1c vs subcutaneous rapid-acting analog (RAA) insulin in youth.

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...

Submission delayed by U.S. government shutdown; initial FDA questions expected during Q4 2025 "The Pivot submission is an exciting milestone in our mission to deliver a differentiated tubeless patch ...

The AID system used in the study is knowns as a Tandem t:slim X2 insulin pump with Control-IQ technology. “We’ve known for a while that AID systems have achieved better glucose control with less ...

The Mobi insulin pump in use. [Image courtesy of Tandem Diabetes Care] This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San ...

DexCom was hit with a recall and several lawsuits after some customers complained about its devices. Despite this current challenge, the medical device leader is delivering solid financial results.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has ...

Patients with type 2 diabetes demonstrated improved glycemic control with the use of automated insulin delivery regardless of baseline C-peptide levels. Automated insulin delivery (AID) systems should ...

Nov 6 (Reuters) - Medical device maker Insulet (PODD.O), opens new tab on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin ...